Peptide Cycling: Why, How Long, and When to Stop

Most research peptides are cycled rather than dosed continuously. The reasons: long-term human-safety data is limited for most compounds, receptor desensitization is real for several mechanism classes (especially GH secretagogues), and a structured washout gives you a clean read on whether the peptide was doing what you thought. This article covers when to cycle, what cycle lengths the literature supports, and how to design loading and maintenance phases.

This article is informational, not medical advice. Cycle decisions belong with a clinician.

When to cycle vs run continuously

Some peptides are designed to be taken indefinitely under clinician supervision — GLP-1 agonists for chronic obesity (Semaglutide, Tirzepatide), HGH for diagnosed growth-hormone deficiency, Tesamorelin for HIV-associated lipodystrophy. Stopping reverses the benefit; cycling makes no clinical sense.

Most other peptides discussed on this site are typically cycled:

Reason to cycle	Applies to
Receptor desensitization	GH secretagogues (Ipamorelin, CJC-1295, MK-677, Hexarelin, GHRP-2/6)
Limited long-term human data	BPC-157, TB-500, most bioregulator peptides, FOXO4-DRI, SS-31
Suppression of native axis	GnRH analogs, Gonadorelin, Kisspeptin if used continuously
Cumulative tachyphylaxis	Melanotan II for tanning, PT-141 for sexual function
Cost / practicality	Any expensive peptide where intermittent dosing maintains benefit
Targeted indication completed	BPC-157 for acute injury healing; cycle ends when the injury heals

Cycle structure: loading, maintenance, washout

Most cycles fit a three-phase shape:

1. Loading phase

Higher dose or higher frequency for a defined ramp-up period. Common with peptides whose downstream effects accumulate over time (TB-500 building tissue-migration capacity, Epitalon building telomerase signal).

Examples:

• TB-500: 2–2.5 mg twice weekly for 4 weeks.
• Epitalon: 5–10 mg daily for 10–20 days.
• MK-677: Some users do 25 mg daily for the first 2 weeks before settling at 12.5 mg.

Not all peptides have a loading phase. BPC-157, GHK-Cu, Selank, Semax, and the GLP-1 class don't typically use one.

2. Maintenance phase

Settled dose at a regular cadence. The bulk of the cycle. Length is peptide-dependent:

Peptide	Typical maintenance length
BPC-157 (acute injury)	4–6 weeks
TB-500 (post-loading)	4–6 weeks weekly dosing
Ipamorelin / CJC-1295	8–12 weeks, then 4 weeks off
MK-677	8–12 weeks, then 4 weeks off
Epitalon	10–20 days, then 6 months off (annual cycle)
Selank / Semax (NA-Selank / NA-Semax)	10–14 day courses
DSIP	5–10 day courses
Cosmetic injected (GHK-Cu)	Variable; often cycled monthly
GLP-1 / GIP agonists	Continuous under clinician supervision

3. Washout phase

No peptide. Usually 2–4 weeks for the recovery-oriented compounds; longer (months) for the longevity / bioregulator peptides which are dosed annually or semi-annually.

The washout serves three purposes:

1. Reassess. Did the peptide actually do what you thought? Take it away and see what reverts.
2. Re-sensitize receptors. Especially relevant for GHRPs.
3. Catch lingering side effects. Issues that built up slowly across the cycle become visible during washout.

How to choose cycle length

A reasonable decision tree:

1. What does the research literature use? Most clinical and animal studies are 4–12 weeks. Default to that unless the indication demands otherwise.
2. What is the indication? Acute injury healing: cycle ends when the injury heals (typically 4–8 weeks). Body-composition: 8–12 weeks gives the effect time to show. Cosmetic: variable; topical use can be continuous, injected often monthly.
3. What did the compound feel like in the first 2 weeks? Strong effect → consider a shorter cycle (less time for tolerance to build). Mild or absent effect → continue and reassess at the typical mark.
4. What is the cost / availability constraint? Some patterns are dictated by what you can afford or source.

Designing your first cycle

A concrete template:

• Week 0: Baseline labs (CBC, CMP, lipid panel, A1C; topic-relevant hormones). Pre-cycle photos / movement tests / measurements depending on the goal.
• Weeks 1–2: Loading phase if the peptide has one. Otherwise start at intended maintenance dose. Daily journal: effects, side effects, anything unusual.
• Weeks 3–8 (or whatever cycle length): Maintenance dose. Continue journaling. Re-take measurements weekly.
• Cycle end: Final measurements + labs.
• Weeks 9–12 (washout): No peptide. Watch what reverts and what persists.
• Post-washout: Decide whether to repeat. If you repeat: same dose? Different dose? Stacked? Don't change more than one variable.

Stacking and cycle structure

When stacking peptides, cycle lengths usually match — both peptides start and stop together. The Wolverine Stack (BPC-157 + TB-500 for healing) is a classic example: 4–6 weeks on, both, then 4 weeks off.

Exception: GH stacks (e.g., CJC-1295 + Ipamorelin) often have both compounds on the same schedule, cycled 8–12 weeks on, 4 weeks off, to allow GH-axis recovery.

Avoid asymmetric cycles (one peptide ending while the other continues) — the attribution becomes impossible if anything changes.

Common cycling mistakes

• No washout. "Just keep going" is the most common mistake. The washout is when you learn what the peptide was actually doing.
• Cycling for the sake of it. GLP-1 agonists for chronic obesity should not be cycled — the indication is chronic, the treatment is chronic. Cycling for a peptide that's working continuously erases gains.
• Loading too aggressively. Doubling the loading dose doesn't double the loading effect; it doubles the side-effect risk.
• Stacking new peptides mid-cycle. Adding a second peptide three weeks in makes attribution of any new effect impossible. Wait for the washout, then plan the next cycle as a stack from week 0.
• Re-starting without reassessing. Each cycle should answer a question; otherwise you're just running a habit.

Where to go from here

• Pick a peptide → browse the library or the category hubs.
• Get the operational guides → how to reconstitute, how to inject.
• Plan the safety frame → are peptides safe?, peptide side effects.
• Read the beginner pillar → how to use peptides.